Veliparib and Temozolomide in Treating Patients With Acute Leukemia

NCT01139970 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

NIH

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A
Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Adult B Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Adult T Acute Lymphoblastic Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Temozolomide
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)